GlassScriptPhysician profile
James L Williams
NPI 1912918491
$11,436.38
in general payments reported to CMS, 2019-2025
45 companies · $597 in 2025
The $597 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,641 · 2020: $1,642 · 2021: $1,968 · 2022: $1,836 · 2023: $1,712 · 2024: $2,041 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,349.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,175.94 | 2021-2024 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $1,133.98 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,090.16 | 2019-2024 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $837.50 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $656.62 | 2019-2024 | |
| Abiomed | $618.18 | 2024-2025 | Impella |
| Janssen Pharmaceuticals, INC | $518.65 | 2019-2022 | |
| Amgen INC. | $450.96 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $438.03 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Mylan Specialty L.P. | $392.59 | 2019-2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $355.49 | 2022-2024 | |
| Allergan, INC. | $341.91 | 2019-2020 | |
| Glaxosmithkline, LLC. | $333.27 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $322.84 | 2021-2024 | Rexulti, Nuedexta, Abilify Maintena |
| Novartis Pharmaceuticals Corporation | $246.66 | 2019-2024 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.